Affordable Access

Botulinum toxin type B for treatment of spasmodic dysphonia: a case report.

Authors
Type
Published Article
Journal
Journal of Voice
0892-1997
Publisher
Elsevier
Publication Date
Volume
16
Issue
3
Pages
422–424
Identifiers
PMID: 12395995
Source
Medline
License
Unknown

Abstract

Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

Statistics

Seen <100 times